Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Myokardia's (MYOK) Mavacamten (MYK-461) in Non-obstructive Hypertrophic cardiomyopathy Phase 2 Data from PIONEER-OLE Study to be presented at ESC August 31

Source Link:: http://spo.escardio.org/SessionDetails.aspx?eevtid=1423&sessId=27696&subSessId=0&searchQuery=/default.aspx%3Feevtid%3D1423%26days%3D%26topics%3D%26types%3D%26rooms%3D%26freetext%3DMavacamten%26sort%3D1%26page%3D1%26showResults%3DTrue%26nbPerPage%3D20%26WithWebcast%3D%26WithSlides%3D%26WithAbstract%3D%26WithReport%3D%26scroll%3D207.3333282470703#.XWAfHOgzY2w

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

MYOK

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Aug 31, 2019

Occurred Source:

https://myokardia.gcs-web.com/news-releases/news-release-details/myokardia-presents-36-week-data-pioneer-ole-study-mavacamten

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Mavacamten, Myk-461, Pioneer-ole, Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy